Tagged with S

France Seven years after our last discussion, GREENTECH has expanded its international presence, reinforced its leadership in dermocosmetics, and deepened its role in pharmaceuticals. In this interview, CEO Jean-Yves Berthon reflects on the group’s evolution, from pioneering natural ingredients for the world’s leading cosmetics brands to advancing biotechnology across plants, microbes,…

Gilead With more than 20 years of experience in the pharmaceutical industry and a track record at companies such as MSD, Abbott (later AbbVie), Eisai and AstraZeneca, Stuart Head brings a deep well of expertise to the Swiss affiliate. His career spans multiple therapeutic areas, including oncology, immunology, and respiratory diseases.…

Switzerland Dr Srishti Gupta brings a distinctive combination of medical training, health policy insight, and strategic consulting to her role as CEO of Idorsia Pharmaceuticals. A Harvard-trained biochemist and physician, she spent 18 years at McKinsey & Company advising life sciences and global health clients. Committed to reducing healthcare inequities and…

Hong Kong Since our last conversation with Tony Cheng in mid-2024, Merck Hong Kong has entered a new phase of consolidation and growth. The affiliate has strengthened its team, accelerated its adoption of AI, and deepened collaborations with the Hong Kong Science and Technology Parks. At the same time, Cheng continues to…

Switzerland Maximilian Schrems,  Managing Director of VTU Engineering AG (Switzerland), brings a distinctive background in architecture and structural engineering to pharmaceutical engineering, an advantage when integrating complex process requirements with advanced facility design. Under his leadership, VTU emphasises operational excellence, high-performance culture, and nearshoring across Europe to ensure project continuity and…

Denmark With decades of experience across nuclear medicine, oncology, and clinical development, Dr Nicholas Borys now leads MedTrace through a pivotal phase as interim CEO and Chief Medical Officer. The Danish company is advancing a novel platform that enables real-time production of oxygen-15 labelled water – a tracer long considered the…

France With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR 750 million investment in a new industrial site and a unique public health mandate, the state-owned player is not just…

Switzerland Fabien Stutz, Co-Founder and CEO of Pharmabotix, leads a new wave of pharma-tech entrepreneurs combining engineering expertise with cutting-edge automation. He has helped grow the Swiss-based company into a globally recognised firm, delivering bespoke systems to major clients across Europe and North America, while retaining the agility of a boutique…

UK Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France have the talent, capital, and healthcare ecosystems to lead. By linking their world-class clusters, aligning regulation, and pooling investment, they…

Switzerland From her beginnings as an operating room nurse to her current role as Head of Varian EMEA, Virve Sarja has shaped a career grounded in purpose and driven by innovation. Today, she reflects on how Varian, as part of Siemens Healthineers, is redefining the future of oncology, bringing together advanced…

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers Gilead’s USD 350mn bet on in vivo CAR-T, GenFleet and Bao Pharma advancing Hong Kong IPOs, Fosun’s USD 670mn global out-licensing deal, new funding rounds for Vibrant and InxMed, and major clinical wins including Akeso’s NSCLC bispecific,…

China Chinese biopharma innovators are making real progress toward global expansion. However, as Vera Zhang of Bristol-Myers Squibb (China) Investment Co., Ltd. writes in DIA’s Global Forum magazine, moving beyond exporting products to building real global brands means investing in strategic international talent acquisition and well-defined roles, all underpinned by a…